NanoViricides Inc. (NNVC)

[KuChing]

MK, You are missing the big picture. NNVC has exclusive, perpetual licenses with TheraCour to “this technology” (from latest 10k). The answer to your question is emphatically, yes. Does NNVC have the rights to sell materials produced by TheraCour? Yes. Have they sold any of these materials? No. It is not a matter of what but when. Can NNVC get to a point of closing a deal with a big pharma, or government agency before capital funding runs dry will be the only real question until the first deal. Then, everything takes off. It is an all or nothing gamble. If not, then all this corporate structure is unnecessary. If yes, then TheraCour will get rich too (through subcontracts for production and equity in NNVC) if NNVC closes the deal. This corporate structure was created to protect the IP and raise capital through public offerings. Will NNVC stock holders get rich if TheraCour gets rich by this scenario? Of course. Could NNVC go toxic? Like any penny stock with no revenue, yes. Have they? No. I think this makes the logic for big pharmas either all in or all out. That is, either make a play for all the promising NNVC antivirals or none. All it takes is one event, like approval by the government for experimental use of FluCide, which they now have the power to do with a stroke of a pen, and we are in orbit.